| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/172.6.1425 |
| P953 | full work available at URL | http://academic.oup.com/jid/article-pdf/172/6/1425/2449362/172-6-1425.pdf |
| P698 | PubMed publication ID | 7594698 |
| P2093 | author name string | A. G. Glass | |
| M. H. Schiffman | |||
| D. Lowy | |||
| R. Kirnbauer | |||
| C. E. Greer | |||
| M. M. Manos | |||
| A. T. Lorincz | |||
| L. Wideroff | |||
| B. Nonnenmacher | |||
| N. Hubbert | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1425-1430 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia | |
| Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical Neoplasia | |||
| P478 | volume | 172 |
| Q36403705 | A history of allergies is associated with reduced risk of oral squamous cell carcinoma |
| Q44687393 | A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children |
| Q35126616 | Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. |
| Q54920076 | Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. |
| Q35566274 | Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination |
| Q45407070 | Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer |
| Q33539323 | Cervical cytology and colposcopy in young patients attending genitourinary medicine clinics: invalid intrusion or preventive opportunity and definitive audit? |
| Q36542076 | Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA |
| Q73733757 | Characterization of IgA response among women with incident HPV 16 infection |
| Q28397067 | Combined p53-related genetic variants together with HPV infection increase oral cancer risk |
| Q36546236 | Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens |
| Q36695693 | Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica |
| Q21144710 | Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses |
| Q34038946 | Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women |
| Q36353396 | Genital human papillomavirus infection in men. |
| Q34542304 | HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays |
| Q33661321 | High risk genital papillomavirus infections are not spread vertically |
| Q45748191 | Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles |
| Q50537413 | Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. |
| Q37227138 | Human papillomavirus infection with particular reference to genital disease |
| Q46959146 | Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China |
| Q41485252 | Human papillomaviruses: general features |
| Q34305225 | Immunity to oncogenic human papillomaviruses |
| Q35562265 | Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection |
| Q45757906 | Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions |
| Q41103016 | Immunology of papillomavirus infection. |
| Q36545052 | Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays. |
| Q64130043 | Lower Genital Tract Infections and HIV in Women |
| Q74534891 | Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia |
| Q35193613 | Papillomavirus vaccines in clinical trials |
| Q34187267 | Papillomaviruses infect cells via a clathrin-dependent pathway |
| Q35228978 | Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women |
| Q40572162 | Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. |
| Q36646726 | Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites |
| Q38110696 | Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme |
| Q47577275 | Risk factors of invasive cervical cancer in Mali |
| Q35228223 | Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. |
| Q37881565 | Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer |
| Q45733679 | Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer |
| Q33936598 | Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA |
| Q33345224 | Seroprevalence of 34 human papillomavirus types in the German general population |
| Q36671130 | Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica |
| Q45044160 | Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations |
| Q45744233 | Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia |
| Q45745124 | Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa |
| Q34579346 | Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay |
| Q26830046 | The contribution of molecular epidemiology to the identification of human carcinogens: current status and future perspectives |
| Q36624010 | The epidemiology of conjunctival squamous cell carcinoma in Uganda |
| Q41485282 | Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses |
| Q45103275 | Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. |
| Q34089060 | Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection |
| Q33704870 | Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infection |
| Q37023158 | p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers |
Search more.